After 30 years at the University of Nottingham Professor David Kendall left on July 31st to work full time as Chief Scientific Officer of our joint companies Pharmnovo AB and Pharmnovo UK Ltd. David has been part-time with the company since 2009 and is excited by the new challenges providedRead More →

Pharmnovo will present its new product, a very selective biased delta opioid receptor agonist for the treatment of chronic pain at the Nordic Life Science Days (NLS Days) on the 9th September in Stockholm.  Pharmnovo will also present its scientific cluster team and describe products in development in the book “LifeRead More →

Dr Patrick Kendall is our new Clinical Business Manager. Patrick will work mainly with plans for the  clinical development program for our delta opioid agonist project. Patrick will also help in establishing Pharmnovo UK Ltd in Liverpool.

Pharmnovo has established a long term partnership with an Angel Investor. In the light of this, the company will start several new projects and a commitment to clinical safety work in the new Pharmnovo UK Ltd.